An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation Therapy (ADT) for Men With Non-metastatic Prostate Cancer That Progressed Following Prior Bicalutamide + ADT Treatment

Inclusion Criteria: * Males Age ≥ 18 years. * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. * Patients receiving ≥6 m ADT+Bicalutamide in nmHSPC, progressed to nmCRPC judged by investigators. * Serum testosterone level\<1.7 nmol/L. * Decision to initiate treatment with ADT + Darolutamide as per investigator's routine treatment practice. * No evidence of metastasis as assessed by computed tomography (CT)/magnetic resonance imaging (MRI) for soft tissue disease and whole-body radionuclide bone scan for bone disease. * The informed consent form must be signed by the patient or his legal guardian (as applicable). * Patients who are fertile must use an effective method of contraception during the study and must refrain from donating sperm during the study or for 3 months after the end of treatment, unless they have undergone a radical prostatectomy. Exclusion Criteria: * Participation in an investigational program with interventions outside of routine clinical practice. * Presence of distant metastases, including involvement of the Central Nervous System (CNS) and vertebral or meningeal involvement. * Symptomatic local or regional lesions requiring medical intervention (moderate or severe urinary tract obstruction or hydronephrosis caused by the primary tumor). * Previous treatment with 2nd-generation ARIs. * Previous treatment with CYP17 inhibitors. * Previous treatment with radiopharmaceuticals, immunotherapy, or other investigational treatment for nmCRPC. * Severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events, or clinically significant ventricular arrhythmias. * Gastrointestinal diseases affecting absorption.